Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4416823 | 1.00 | SLC6A2 (0.37) | SLC6A2SLC6A4TDP1TP53MAPT | |
| SCHEMBL4259232 | 0.91 | TDP1 (0.42) | TDP1MAPTAOC3KDM4EALDH1A1 | |
| SCHEMBL4259511 | 0.91 | TDP1 (0.42) | TDP1MAPTAOC3KDM4EALDH1A1 | |
| SCHEMBL493770 | 0.83 | SLC6A2 (0.35) | SLC6A2SLC6A4TDP1KDM4EALDH1A1 | |
| SCHEMBL4259328 | 0.83 | SLC6A2 (0.35) | SLC6A2SLC6A4TDP1KDM4EALDH1A1 | |
| SCHEMBL4262564 | 0.79 | TDP1 (0.43) | TDP1MAPTAOC3KDM4EALDH1A1 | |
| SCHEMBL4265627 | 0.79 | TDP1 (0.43) | TDP1MAPTAOC3KDM4EALDH1A1 | |
| Lithium Ion SCHEMBL6002733 | 0.79 | SLC6A2 (0.33) | SLC6A2SLC6A4TDP1KDM4EALDH1A1 | |
| SCHEMBL4256188 | 0.73 | TACR1 (0.36) | TDP1AOC3SMN1; SMN2 | |
| SCHEMBL4261669 | 0.73 | TACR1 (0.36) | AOC3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636221-B1 | 3-Heterocyclyl-Azetidine compounds useful as NK1/NK2 receptors antagonists | ALBIREO AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| US-7402581-B2 | Azetidine compounds | ALBIREO AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20060172988-A1 | Azetidine compounds | ALBIREO AB (SE) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060172988-A1 | Azetidine compounds | HRH2, HRH4, HRH1 | SLC6A2 334/4885SLC6A4 154/4885TDP1 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.